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Abstract
Background: Initially identified as a molecule that regulates the final step of glycolysis, the M2 isoform of pyruvate
kinase (PKM2) was recently reported to have a central role in the metabolic reprogramming of cancer cells as well
as participating in cell cycle progression and gene transcription. Despite intensive efforts, the intricate molecular
mechanisms through which PKM2 regulates tumor progression remain elusive.
Methods: The proliferation and apoptosis of various pancreatic cancer cells using lentiviral-mediated PKM2
abrogation were assessed in vitro via Western blot and flow cytometric assay while the in vivo experiments involved
tumor xenograft on chicken chorionallantoic membranes and immunohistochemistry on human tissue specimens.
In order to decipher the molecular mechanism of HIF-1α and p65/RelA regulation by PKM2 in cancer cells
cultivated in hypoxic atmosphere or normoxia we involved various biochemical assays such as Western blotting,
immunoprecipitation, reporter gene assay and ELISA.
Results: Strong expression of PKM2 was observed in 68 % of human pancreatic adenocarcinoma specimens and
almost all analyzed pancreatic cancer cell lines. Abrogation of PKM2 resulted in impaired proliferation and
augmented apoptosis in vitro as well as impaired tumor growth and decreased blood vessel formation in vivo.
Furthermore, deletion of PKM2 negatively impacted hypoxia-induced HIF-1α accumulation and promoter activity
ultimately resulting in impaired secretion of VEGF.
Conclusions: Our study suggests that in hypoxic pancreatic tumors PKM2 interferes both with NF-κB/p65 and
HIF-1α activation that ultimately triggers VEGF-A secretion and subsequent blood vessel formation.
Keywords: Pancreatic cancer, Tumor growth, Tumor angiogenesis, Apoptosis, Hypoxia, PKM2, p65/RelA,
HIF-1α, CAM
Background
The primary function of pyruvate kinase (PK) enzyme is
to regulate the final rate-limiting step of glycolysis,
which catalyzes the transfer of a phosphate group from
phosphoenolpyruvate (PEP) to adenosine disphosphate
(ADP), yielding one molecule of pyruvate and one mol-
ecule of adenosine triphosphate (ATP) [1]. There are
four pyruvate kinase isoenzymes: PKR (expressed in red
blood cells), PKL (the liver isoform), PKM1 (found in
heart, brain and muscle) and PKM2 (upregulated in em-
bryonic and tumor cells) [2]. PKM1 and PKM2 isoforms
are produced upon mutually exclusive alternative spli-
cing of the PKM pre-mRNA, reflecting the inclusion of
either exon 9 (PKM1) or exon 10 (PKM2), respectively
[3]. Due to its upregulation in various tumors, PKM2
has garnered attention and was demonstrated to play an
essential role in tumor progression [4, 5]. It is worth
noting that PKM2 expression levels vary among different
types of cancer [6] suggesting that PKM2’s role in
tumorigenesis depends on signaling context. Several
studies indicate that PKM2 regulates apoptosis and pro-
liferation [7–9]. While siRNA-mediated PKM2 ablation
resulted in caspase-mediated apoptosis and tumor re-
gression in vivo [10, 11], somatostatin-induced nuclear
translocation of PKM2 was associated with the induction
of cell death in a caspase-independent manner [8]. A
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recent view on how elevated levels of PKM2 would
benefit proliferating tumor cells is based on the recent
findings that PKM2, but not PKM1, can translocate to
the nucleus and act both as a protein kinase and as tran-
scriptional coactivator for hypoxia-inducible factor alpha
(HIF-1α) in HeLa cervical carcinoma cells [12]. In this
study, Luo and colleagues demonstrated that HIF-1α
binds hypoxia response elements (HRE) within the first
intron of human PKM2 that contains a HIF-1-binding
site (5′-ACGTG-3′) followed by a 5′-CACA-3′ se-
quence. PKM2 physically interacts with HIF-1α in the
nuclei of hypoxic human cancer cells and promotes
transactivation of HIF-1α target genes by enhancing the
recruitment of p300 to HRE sites [12]. Similarly, phos-
phoinositide 3-kinase (PI3K) activation has been shown
to increase PKM2 expression through HIF-1α-regulated
transcription of the PKM gene [12, 13]. PKM2 has also
been demonstrated to participate in transcriptional acti-
vation in response to epidermal growth factor (EGF) [4]
and to interact, cooperate with, and be regulated by Oct-
4 [9, 14]. Only very recently, PKM2 was reported to
interact with NF-κB subunit p65/RelA and to promote
tumor angiogenesis and cancer progression [15]. In this
study, the authors demonstrated that activation of IGF-
1/IGF-1R induces HIF-1α/p65 complex formation,
which thus binds to the PKM promoter region leading
to PKM2 upregulation and PKM2-mediated breast can-
cer cell growth. Several studies indicated that control of
HIF-1α gene by NF-κB provides an important, additional
and parallel level of regulation over the HIF-1α pathway
[16–19]. Moreover, in the absence of NF-κB, the HIF-1α
gene is not transcribed and therefore no stabilization and
activity is observed even after prolonged hypoxia [18, 19].
In this study, we investigated the role of PKM2 in
angiogenesis of hypoxic pancreatic tumors. We found
that PKM2 is expressed in human pancreatic adeno-
carcinoma and controls VEGF-A secretion by regulat-
ing both HIF-1α and NF-κB. Our study favors a
signaling mechanism which places the HIF system as
a downstream effector of NF-κB biological functions
and indicate PKM2 as a kinase that acts upstream of
these two transcription factors in hypoxic pancreatic
tumors.
Methods
Cell lines and reagents
Human pancreatic cancer cell lines used in the study
are: Capan1, adenocarcinoma cells derived from pancre-
atic metastatic site, #ATCC HTB-79; Panc1, a pancreatic
epitheloid carcinoma cell line, #ATCC CRL-1469;
BxPC3, pancreas adenocarcinoma cells, #ATCC CRL-
1687 and Mia Paca-2 carcinoma cells, #ATCC CRL-
1420. PaTu2 and PancTu1 pancreatic adenocarcinoma
cells were kindly provided by Prof. Simone Fulda, Insti-
tute for Experimental Cancer Research in Pediatrics,
Frankfurt, Germany. BxPC3 and Capan1 were used for
in vivo investigations due to their ability to form tumors.
Due to higher transient transfection efficacy, PaTu2 and
Capan1 were involved in reporter assays and ELISA. Cell
lines of early passages were cultured in DMEM (Invitro-
gen, Germany) supplemented with 10 % fetal calf serum
(FCS: Biochrom / Millipore, Germany), 1 % penicillin/
streptomycin. BAY 87-2243 was purchased from Seleck-
chem (#S7309), TEPP-46 was from Millipore (#5.05
487.0001).
Short hairpins, plasmids, lentiviral transduction and
transfection
PKM2-specific shRNAs originate from the “MISSION
shRNA Library” designed and developed by the TRC
at the Broad Institute of MIT and Harvard. Two
PKM2 hairpins (NM_182471.1-1706s1c1- #2 and
NM_182471.1-1493s1c1- #4) that showed high efficacy
knock-down were selected. The TRC lentiviral human
p65/RelA shRNAs were purchased from Thermo Scien-
tific, GE Dharmacon (#RHS4533-EG5970). The most effi-
cient two p65-specific shRNAs (TRCN0000014684-F12
and TRCN0000014687-G3) were used for experiments.
The pcDNA3-YFP-p65 expression plasmid was a kind gift
from Dr. Franz Oswald, University Hospital of Ulm;
pcDNA3-HIF-1α was obtained from Addgene (HIF-1α,
#18949). High-titer virus-containing supernatants of
HEK293FT cells after transient co-transfection of len-
tiviral vectors with pMD2.G and psPAX2 packaging
vectors were used for lentiviral mediated transduction
of cancer cells.
(See figure on previous page.)
Fig. 1 PKM2 is highly expressed in human pancreatic tumor specimens. a patient and clinic-pathological data including tumor localization and
site of metastasis of the human pancreatic specimens taken into the study are presented. b Tumor grading of 34 human pancreatic specimens
are shown. c PKM2 immunoreactivity was analyzed using standardized protocols. All cancer samples exhibited “moderate” to “strong” PKM2
staining intensity and therefore grouped accordingly. Representative image of each set is depicted. d Number of human pancreatic tumors
belonging to each grading category and PKM2 immunoreactivity group is presented. e PKM2 staining intensity of blood vessels in the same
tumor specimens were classified according to immunoreactivity intensity in “high”, “intermediate” and “low”. f Bar graph presents the comparison
of PKM2 expression levels in tumor-derived blood vessels and human pancreatic tumors. g lysates of various pancreatic cancer cell lines were
subjected to western blot analysis. Membranes were incubated with PKM2-specific antibody. Quantification of PKM2 band intensity normalized
to β-actin was conducted with the ImageJ software. HEK 293 T cells were used as reference (T – tumor; PT – primary tumor; M – metastasis;
NN – non-neoplastic tissue; G1 – grade 1; G2 – grade 2 and G3 – grade 3)
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Promoter assays
Cancer cells plated in 12-well dishes were transfected
with 330 ng/ml of the respective promoter plasmid as
indicated in the figure legends using Lipofectamine 2000
(Invitrogen #15338-100) or Fugene HD (Promega
#E231A) according to the manufacturer instructions. Lu-
ciferase activity was determined using the Dual Lucifer-
ase Assay Kit (Promega, Mannheim, Germany). Firefly
luciferase units were normalized with Renilla luciferase
after co-transfection with 17 ng/ml pRL-TK plasmid
(Promega, Germany).
CAM assay
BxPC3 and Capan1 pancreatic cancer cells (1 × 106)
transduced with shPKM2 or non-coding shRNA were
xenografted within a 5 mm silicon ring on the surface
of the chorionallantoic membrane (CAM) of chicken
eggs 8 days after fertilization. Four days after implant-
ation (day 12 after fertilization), tumors were re-
trieved, fixed in formalin and further subjected to
immunohistochemistry.
Immunohistochemistry of CAM and mouse tumors
Formalin-fixed tumors were embedded in paraffin using
standard procedures. The 5 μm sections were processed
and stained with antibodies directed against Ki67 (1:100;
Dako, clone MIB-1), desmin (1:80; Dako, clone D33) and
von Willebrand Factor VIII (1:100; Biocare Medical,
#CP039B).
Patient samples and ethics statement
All patient samples had been submitted to the Institutes
of Pathology of the Bundeswehrkrankenhaus Ulm or the
University Hospital Münster for routine diagnostic pur-
poses between 2003 and 2015. Patient and clinic-
pathological data including tumor localization and site
of metastasis were obtained from the respective path-
ology report archives. All samples have been anonymized
thoroughly for the use in the study. This study has been
approved by the local ethics committee of the University
of Münster, Germany (No. 2015-102-f-S).
Immunohistochemistry and image acquisition of human
samples
Immunohistochemistry for PKM2 and CD31 was per-
formed on 4 μm FFPE tissue slides that displayed the
invasive margin of the tumors on a Ventana Bench-
Mark Autostainer (Ventana, Tucson, USA) using
PKM2 antibody (Abcam, #ab55602, 1:1000) and
mouse monoclonal antibody against CD31 (clone
JC70, Ventana, Tucson, USA, prediluted) following
the manufacturer’s protocol. Light microscopy and
image acquisition was performed using a Leica
DM6000B light microscope (Leica, Wetzlar, Germany)
and the Diskus Mikroskopische Diskussion image ac-
quisition software (Carl Hilgers, Königswinter,
Germany). PKM2 staining intensity was graded as
negative/weak, moderate, or strong.
Western blot and immunoprecipitation
Whole cell extracts were prepared using IP lysis buf-
fer containing 10 mM Tris-HCl, 5 mM EDTA,
50 mM NaCl, 50 mM NaF and 1 % Triton X100 sup-
plemented with Complete Protease inhibitor Cocktail
and PhosStop tablets (Roche). Lysates were subjected
to SDS-PAGE and proteins transferred to PVDF
membranes (Millipore, Massachusetts, USA). For
coIP, protein extracts (0.5 -1.5 mg) were incubated
with 2 μg antibody and Protein G-Sepharose (GE
Healthcare). Membranes were blocked with 5 % non-
fat dry milk in phosphate buffered saline (PBS) con-
taining 0.2 % Tween 20 and incubated over night at
4 °C with specific antibodies. For subsequent washes
0.2 % Tween 20 in PBS was used. The following
antibodies were used: PKM2 (Abcam, #ab55602);
cleaved PARP (Cell Signaling, #9542S); HIF-1α (BD
Transduction Laboratories, #610959); p65/RelA C-20
(Santa Cruz, #sc-372), GFP (Roche, # 1052 1400) and
β-actin (Sigma, #A1978). Bands were quantified by
densitometric analysis using ImageJ software http://
imagej.net.
FACS analysis
Annexin-V/propidium iodide (PI) staining was per-
formed via flow cytometry according to the manufac-
turer’s guidelines as previously described [20]. Flow
(See figure on previous page.)
Fig. 2 PKM2 depletion is associated with impaired proliferation and augmented apoptosis in tumor cells. a 15 × 103 Capan1, BxPC3 and Panc1
pancreatic cancer cells transiently transduced either with a PKM2-specific shRNA or a non-coding shRNA (shScr) were plated in 24 well dishes and
allowed to grow for the next 120 h. Cell number was quantified every 24 h. Error bars represent mean +/- SEM of two independent experiments
performed in triplicate. b lysates of transiently transduced cancer cells were subjected to western blot analysis with PKM2 antibody as indicated.
β-actin was used as loading control. c various pancreatic cancer cells were stably transduced with two PKM2-specific shRNAs (shPKM2 #2 or
shPKM2 #4) or a non-targeting shRNA (shScr). Lysates were prepared and subjected to SDS-PAGE analysis. Membranes were incubated with PKM2
and cleaved PARP antibodies. d PaTu2 pancreatic cancer cells stably infected with PKM2-specific shRNAs or a non-targeting shRNA were
subjected to annexin V / propidium iodide staining and subsequent flow cytometry. The experiment was performed in triplicate and the data is
shown as mean +/- SEM. One of the two experiments is shown




Fig. 3 PKM2 abrogation results in impaired tumor growth and decreased blood vessel formation in vivo. a BxPC3 and Capan1 cells stably
transduced with PKM2-specific shRNAs (shKM2 #2 and shPKM2 #4) or a non-coding shRNA (shScr) were delivered to CAM on day 8 after
fertilization. Tumor formation was monitored for 96 h. Bar, 1 mm. b quantification of tumor area is presented. Error bars represent mean +/- SEM
of five to seven tumors. c IHC of Capan1 cells growing on CAM using specific antibodies directed against Ki67, desmin and von Willebrand factor
(vWF) is presented. Bar, 125 μm. d quantification of Ki67 positive BxPC3 or Capan1 cells is shown. Error bars represent mean +/- SEM of at least
six microscopic fields, each containing at least 250 cells. e desmin and (f) vWF immunoreactivities in Capan1 cells were quantified by subtracting
background staining from specific signal using Image J software
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cytometric analysis was performed using FACSCalibur
(Becton Dickinson) and the data was analyzed by FlowJo
software.
Hypoxia experiments
The hypoxic environment was generated using the
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#1.01611.0001). Cells were incubated under low oxygen
atmosphere for 8–24 h at 37 °C.
Statistics
Statistical analysis was performed with GraphPad Prism 5.0
software (GraphPad Software, Inc, La Jolla, CA, USA). Stat-
istical significance was assessed by an unpaired student t
test. p < 0.05 or less was considered significant. The quanti-
tative analysis of immunohistology staining was performed
with Image J software (National Institute of Health, Be-
thesda, MD, USA) using the Colour Deconvolution plugin.
Results
PKM2 is highly expressed in human pancreatic tumor
specimens
PKM2 is expressed in tumors of various tissue origins. We
examined the expression of PKM2 by immunohistochem-
istry in a set of 34 human primary pancreatic ductal
adenocarcinomas or metastases to liver, soft tissue, lymph
node and lung (Fig. 1a). 63.63 % of the primary tumors
were classified as grade 2, 13.63 % grade 1 and 22.72 %
grade 3 respectively (Fig. 1b). Virtually all tumor speci-
mens stained positive for PKM2 with 68 % showing strong
and 32 % moderate PKM2 immunoreactivity (Fig. 1c-d).
PKM2 was not only expressed in the tumor tissue but also
in the accompanying vasculature where 15 % of specimens
displayed high, 32 % intermediate and 53 % weak expres-
sion levels (Fig. 1e-f). This is also supported by our CD31
stainings on human pancreatic cancer specimens showing
a dense peritumoral vascular network (Additional file 1:
Figure S1). Similar to the pancreatic cancer specimens, all
pancreatic adenocarcinoma cancer cell lines investigated
expressed elevated levels of PKM2 (Fig. 1g). Altogether,
these data suggest that PKM2 may play an important role
in pancreatic cancer.
Effect of PKM2 depletion on tumor cell proliferation and
tumor cell viability
The presence of PKM2 in embryonic tissues is a first
sign of its importance for proliferating cells. Cancer cells
are highly proliferative and PKM2 has been reported to
be important for growth of tumors originating from vari-
ous tissues such as colon carcinoma, hepatocellular car-
cinoma and ovarian carcinoma [10]. In order to study
the role of PKM2, various pancreatic cancer cell lines
were transduced with PKM2-specific shRNAs or a non-
targeting shRNA. Abrogation of PKM2 closely correlated
with a marked reduction of cell proliferation whereas
scrambled (non-targeting) shRNA showed no effect
(Fig. 2a and b). To investigate whether PKM2 is crucial
for viability of pancreatic cancer cells, we analyzed PARP
cleavage by Western blotting. Abrogation of PKM2 in
several pancreatic cancer cell lines resulted in aug-
mented cleaved PARP levels (Fig. 2c). We substantiated
these results by determination of apoptosis by annexin
V/propidium iodide (PI) staining in PaTu2 cancer cells
(Fig. 2d).
PKM2 depletion in pancreatic cancer cells results in
impaired tumor growth and angiogenesis in vivo
Having determined that PKM2 is required for pancreatic
cancer cell growth in vitro, we further evaluated the ef-
fect of PKM2 silencing in tumor formation in vivo using
the chicken chorionallantoic membrane (CAM), an
established model of in vivo tumor formation [21, 22].
BxPC3 and Capan1 pancreatic cancer cells were trans-
duced with either scrambled oligonucleotide or two
PKM2-specific shRNAs and seeded on the surface of
CAM eight days after egg fertilization. Four days after
implantation, tumors were excised, photographed and
analyzed by IHC. BxPC3 and Capan1 control cells
formed substantial tumors on the CAM whereas trans-
duction with shRNA targeting PKM2 resulted in signifi-
cant decrease of tumor size in vivo (Fig. 3a and b). This
corresponded to significantly reduced proliferation
index, as evidenced by the number of Ki67 positive
tumor cells (Fig. 3c–d and data not shown). Pancreatic
tumors xenografted on chicken CAM trigger formation
of an intense de novo vascularization, both in the tumor
inner core and in the surrounding CAM tissue
(Additional file 2: Figure S2). Interestingly, the impaired
(See figure on previous page.)
Fig. 4 PKM2 regulates hypoxia-induced HIF-1α accumulation and VEGF-A secretion. a, b PaTu2 cancer cells were transfected with either a
GFP-PKM2 construct or GFP empty vector and incubated in normoxic (No) or hypoxic atmosphere (Hy). Forty hours after transfection cells were
subjected to immunofluorescence microscopy. c immunoprecipitation of endogenous PKM2 was performed with lysates of PaTu2 cultivated in
normoxic or hypoxic condition. Membranes were incubated with HIF-1α and PKM2 antibodies. d pancreatic cancer cells transduced with a
non-targeting control shRNA or PKM2-specific shRNAs were incubated under hypoxia or normoxia for 8 h and HIF-1α levels were determined
using western blot analysis. β-actin was used as loading control. e pancreatic cancer cells were transiently transfected with 3xHRE-luc and pTK-
Renilla and then incubated under normoxic or hypoxic conditions as indicated. Cell lysates were subjected to luciferase assay. Bars are the means
+/- SEM of at least three independent experiments. f PaTu2 and Capan1 cancer cell lines with abrogated PKM2 were transiently transfected with
VEGF-A-luc and pTK-Renilla. Four hours after transfection cells were incubated under normoxic or hypoxic conditions and then cell lysates were
subjected to luciferase assay. Bars are the means +/- SEM of at least two independent experiments performed in duplicate. g supernatants of
pancreatic cancer cells transduced with PKM2-specific shRNAs or a non-coding shRNA incubated in low oxygen were subjected to VEGF-A-
specific ELISA. Bars are the means +/- SEM of at least two independent experiments conducted in duplicate
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proliferation of tumor cells transduced with shPKM2
was associated with decreased blood vessel formation of
both intratumoral and extratumoral origin/vessels as re-
vealed by reduced immunoreactivity of von Willebrand
Factor (vWF) and desmin (Fig. 3c, e–f and Additional
file 3: Figure S3).
Hypoxia induces the nuclear translocation of PKM2 and
enhances its interaction with HIF-1α
We next sought to investigate the potential mechanism
through which PKM2 might regulate blood vessel for-
mation in our experiments presented in Fig. 3. Recently,
PKM2 was reported to regulate glucose metabolism by
functioning as a coactivator for HIF-1α in cancer cells
[12]. Interestingly, we had previously shown that in
CAM pancreatic cancer xenografts, augmented tumor
vascularization was associated with high expression of
HIF-1α in the nuclei [22]. Therefore we wanted to find
out whether PKM2 regulates this oxygen sensor mol-
ecule. Since gene transactivation is a function of nuclear
PKM2, we sought to investigate whether hypoxic envir-
onment not only triggers HIF-1α accumulation but also
drives the translocation of PKM2 to the nucleus. For
these experiments we have utilized a GFP-tagged PKM2
construct (Fig. 4a). Hypoxic cultivation of pancreatic
cancer cells transiently expressing GFP-PKM2 resulted
in translocation of PKM2 to the nucleus (Fig. 4b). Fur-
thermore, PKM2 translocation was associated with its
interaction with hypoxia-stabilized HIF-1α (Fig. 4c), in
line with the data presented by Luo and colleagues [12].
PKM2 knock-down is associated with impaired hypoxia-
induced HIF-1α accumulation and VEGF secretion
The nuclear translocation and interaction with HIF-1α
posed the question whether PKM2 was able to regulate
the expression of this oxygen sensor protein under hyp-
oxic conditions. In our experimental setup using pancre-
atic tumor cells, abrogation of PKM2 negatively
impacted hypoxia-induced accumulation of HIF-1α
(Fig. 4d, Additional file 4: Figure S4A-B). Furthermore,
impaired HIF-1α accumulation was associated with sig-
nificant reduction of transcriptional activation of the
HIF-responsive element (HRE), a HIF-1α-docking site
present in promoters that contain the RCGTG sequence
(Fig. 4e). Since upregulation of VEGF-A, an essential
driver of blood vessel formation, occurs mainly via
stabilization of HIF-1α, we sought to investigate whether
PKM2 contributes to VEGF secretion in hypoxic pancre-
atic cancer cells. ELISA experiments demonstrate that
impaired HIF-1α accumulation following depletion of
PKM2 was corroborated with impaired low oxygen-
driven VEGF promoter activity (Fig. 4f ) and decreased
levels of hypoxia-induced secreted VEGF-A (Fig. 4g).
Same effects were obtained with either TEPP-46, a se-
lective activator molecule reported to force PKM2 into
the tetrameric form triggering thus its nuclear exclusion
[23] or BAY 87-2243, an HIF-1α-specific inhibitor. Incu-
bation with TEPP-46 or BAY 87-2243 resulted in im-
paired transcriptional activity of both HIF-1α and
VEGF-A in hypoxic pancreatic cancer cells (Additional
file 5: Figure S5A–D).
PKM2 contributes to VEGF secretion in pancreatic cancer
cells via activation of NF-κB transcription factors
The above mentioned data suggest that PKM2 promotes
hypoxia-induced VEGF secretion via regulation of HIF-
1α. Notably, VEGF-A is not only a target of HIF-1α but
also of NF-κB transcription factors. Quite recently,
PKM2 was shown to translocate to the nucleus and to
interact with p65/NF-κB [15]. Our experiments also
show that PKM2 translocates to the nucleus during hyp-
oxia (Fig. 4b) and furthermore, interacts with the NF-κB
subunit p65/RelA in pancreatic cancer cells (Fig. 5a), in
line with data by Xu and colleagues [15]. We next hy-
pothesized that such an interaction might contribute to
VEGF secretion, and therefore depletion of either of
PKM2 or p65 would affect VEGF expression. Similar to
PKM2, shRNA-mediated depletion of p65/RelA resulted
in impaired hypoxia-induced VEGF transcriptional activ-
ity (Fig. 5b-c) and decreased hypoxia-stimulated VEGF
(See figure on previous page.)
Fig. 5 PKM2 mediates hypoxia-triggered VEGF-A secretion by activation of NF-κB/p65 subunit. a immunoprecipitation of endogenous p65 was
performed with lysates of PaTu2 and BxPC3 cells. Membranes were incubated with PKM2 and reprobed with p65 antibodies. b, c PaTu2 and
Capan1 cancer cell lines with abrogated p65/Rel (shp65 #G3 or shp65 #F12) were transiently transfected with VEGF-A-luc and pTK-Renilla. Four
hours later cells were subjected to normoxic or hypoxic conditions. After 24 h cell lysates were prepared and subjected to luciferase assay. Bars
are the means +/- SEM of at least three independent experiments. d supernatants of PaTu2 or Capan1 cells transduced with p65/RelA-specific
shRNA (shp65) or a non-coding shRNA incubated in low oxygen were subjected to VEGF-A-specific ELISA. Bars are the means +/- SEM of at least
two independent experiments conducted in duplicate. e PaTu2 and Capan1 cancer cell lines with abrogated PKM2 were transiently transfected
with 3xκB-luc and pTK-Renilla. After incubation under normoxic or hypoxic conditions cell lysates were prepared and reporter activity assayed.
Bars are the means +/- SEM of at least three independent experiments. f, g pancreatic Capan1 cells with abrogated PKM2 were transiently
co-transfected with p65 and VEGF-A-luc reporter before incubation in low oxygen atmosphere. Luciferase was measured after 24 h. h
supernatants of Capan1 cells with deleted PKM2 and overexpressing p65 cultivated in O2-deprived atmosphere or normoxia were subjected
to VEGF-A-specific ELISA. Bars are the means +/- SEM of at least two independent experiments conducted in duplicate (No – normoxia; Hy
– hypoxia)
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secretion (Fig. 5d) in pancreatic cancer cells. Interest-
ingly, abrogation of PKM2 was also associated with im-
paired hypoxia-induced NF-κB transcriptional activity
(Fig. 5e) suggesting that PKM2 might regulate VEGF se-
cretion via NF-κB transcription factors. Indeed, ectopic
expression of p65/RelA restored hypoxia-induced VEGF
promoter activity and secretion after ablation of PKM2
in Capan1 (Fig. 5f-h) and PaTu2 cancer cells (Additional
file 6: Figure S6A-C).
PKM2 regulates HIF-1α -induced VEGF secretion in a NF-
κB/p65-dependent manner
In pancreatic cancer cells, PKM2 appears to regulate
hypoxia-induced transcriptional activity of both HIF-1α
(Fig. 4e) and NF-κB (Fig. 5e) culminating in VEGF tran-
scription and secretion (Figs. 4f-g; 5g-h and Additional
file 6: Figure S6A-C). This suggests that PKM2 partici-
pates in the intricate cross-talk between NF-κB and
HIF-1α and urged us to elucidate the potential chron-
ology of the signaling events in hypoxic cancer cells
leading to VEGF secretion. Belaiba and colleagues dem-
onstrated that in hypoxic cells nuclear NF-κB subunits
interact with the κB binding site in the HIF-1α promoter
at -197/-188 bp, and thus increase HIF-1α promoter ac-
tivity and HIF-1α expression [24]. In line with this, we
could show that ectopic expression of p65/RelA in pan-
creatic cancer cells results in augmented HIF-1α accu-
mulation and promoter activity already in normoxic
condition (Fig. 6a and b). Conversely, p65 knock-down
prevented the activation of HRE in hypoxic cells (Fig. 6c)
in line with previous data [18, 19]. Interestingly, overex-
pression of PKM2 in cancer cells with abrogated p65/
RelA had a minimal effect on HIF promoter activity
(Fig. 6d). At the same time, ectopic p65/RelA was able
to restore hypoxia-induced HIF promoter activity after
abrogation of PKM2 in hypoxic pancreatic cancer cells
(Fig. 6e). These data suggest that p65 acts upstream of
HIF-1α and downstream of PKM2 in pancreatic cancer
cells. This hypothesis is supported also by the fact that
overexpression of HIF-1α in cells with deleted PKM2
showed only a marginal effect on NF-κB promoter activ-
ity (Fig. 6f ).
Discussion
The primary function of pyruvate kinase M2 isoform
(PKM2) is to catalyze the phosphorylation from phospho-
enolpyruvate (PEP) to pyruvate as the last step of glycoly-
sis to generate ATP. Incidentally, tumor cells need a
permanent supply of glycolytic intermediates [25, 26] and
an impaired activity of PKM2 (through dimer formation)
was observed to favor rapid cell proliferation. Several
studies from recent years demonstrated that PKM2 may
play a far broader role in promoting cancer progression
than has previously been appreciated. However, the intri-
cate molecular mechanisms through which PKM2 exerts
its tumorigenic role remain elusive.
In this study, we have identified PKM2 as a crucial
molecule for progression of pancreatic cancer in which
the tumor microenvironment has been reported to be
highly hypoxic [27]. Accordingly, we found moderate to
strong PKM2 expression in all examined human pancre-
atic adenocarcinoma samples. Depletion of PKM2 was
associated with impaired proliferation and augmented
tumor cell death in vitro, while the in vivo tumor xeno-
graft experiments revealed a close association between
impaired tumor growth and decreased blood vessel for-
mation. These findings, together with earlier studies
showing that PKM2 promotes angiogenesis by binding
to TEM8 - tumor endothelial factor 8 [28], suggest that
PKM2 might contribute to tumor growth by regulating
crucial molecules involved in tumor vascularization.
Such a molecule is the well characterized VEGF. The
fact that VEGF is directly regulated by HIF-1α, an oxy-
gen sensor protein reported to interact with PKM2 [12]
urged us to evaluate the role of PKM2 with respect to
HIF-1α stabilization and VEGF secretion in hypoxic
pancreatic tumors. Firstly, we showed that PKM2 trans-
locates to the nucleus in pancreatic cancer cells culti-
vated in hypoxic conditions. Secondly, the interaction
between PKM2 and HIF-1α is augmented in hypoxic
cancer cells. Lastly, abrogation of PKM2 prevented
(See figure on previous page.)
Fig. 6 PKM2 regulates HIF-1α transcription via activation of NF-κB signaling pathway. a pancreatic cancer cells were transiently transfected with a
p65 expression plasmid (YFP-p65). In parallel, cells transfected with control empty vector (GFP-empty) were cultivated in normoxia or hypoxia for
8 h. Lysates were subjected to SDS-PAGE and membranes were incubated with HIF-1α and p65 antibodies. β-actin was used as loading control.
b PaTu2 cells were co-transfected with p65 and HIF-1α reporter. After incubation for 24 h in low oxygen atmosphere, lysates were prepared and
luciferase was measured. c cancer cells with abrogated p65 were transfected 3xHRE-luc and then incubated in low oxygen atmosphere. Luciferase
was measured 28 h after transfection. Bars are the means +/- SEM of at least three independent experiments. d PaTu2 cells featuring p65 knock-
down were co-transfected with PKM2 expression plasmid and 3xHRE-luc and then grown in an atmosphere deprived of oxygen. Luciferase was
scored 24 h later. Bars are the means +/- SEM of at least three independent experiments. e PaTu2 and Capan1 cancer cells with depleted PKM2
were co-transfected with a p65 expression plasmid and 3xHRE-luc and then grown in an atmosphere deprived of oxygen. Luciferase was scored
24 h later. Bars are the means +/- SEM of at least three independent experiments. f PaTu2 cells with abrogated PKM2 were co-transfected with a
HIF-1α expression plasmid and a 3xκB-luc reporter and then grown in hypoxia. Luciferase was scored 24 h later. Bars are the means +/- SEM of at
least three independent experiments. For all reporter assays TK-Renilla was used as internal control
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hypoxia-mediated HIF-1α accumulation and HIF-1α
promoter activity, which negatively impacted VEGF se-
cretion by pancreatic cancer cells deprived of oxygen.
Together, these findings suggest that PKM2 is required
for HIF-1α mediated VEGF transcriptional activity and
secretion. Hypoxia not only results in the accumulation
A B
Fig. 7 PKM2 contributes to tumor growth and angiogenesis by regulating HIF-1α via NF-κB activation. a in physiological conditions PKM2 and
p65 reside in the cytosol. Hypoxic insult is followed by translocation of PKM2 and p65 to the nucleus in pancreatic cancer cells. Following the
interaction with PKM2, NF-κB subunit p65 activates the transcription of HIF-1α and its target gene VEGF-A. As a result, augmented secretion of
VEGF translates to a boost in blood vessel formation, which in turn contributes to tumor growth. b in the absence of PKM2, transcription and
secretion of VEGF-A is still present, yet to a lower level. While our data do not exclude the VEGF secretion as a result of sole NF-κB activation or
HIF-1α accumulation, they emphasize the essential role of PKM2 in the regulation of HIF-1α and NF-κB transcription factor during tumor
angiogenesis and tumor growth of hypoxic pancreatic tumors
Azoitei et al. Molecular Cancer  (2016) 15:3 Page 13 of 15
of HIF-1α, but also activates the NF-κB transcription
factors [29]. Because PKM2 was reported to directly
interact with the NF-κB p65 subunit to promote EGR1
expression [15], we explored the possibility whether
PKM2 interferes with NF-κB activation by hypoxia. In-
deed, PKM2 expression arrest was mirrored by impaired
hypoxia-driven promoter activity of NF-κB and its target
gene VEGF. Ectopic expression of p65 restored VEGF
transcription after PKM2 ablation inferring that the kin-
ase regulates VEGF via NF-κB p65 subunit. This finding
is also supported by the fact that PKM2 interacts with
p65 in pancreatic cancer cells. It has been previously
shown that activation of NF-κB and transcript abun-
dance of p65 are diminished in HIF-1α-deficient mice
[30] and that the NF-κB subunits translocated to the nu-
cleus interact with the NF-κB binding sites in the HIF-
1α promoter, thus increasing HIF-1α promoter activity
and expression [18, 24]. The fact that HIF-1α itself con-
tributes to the activation of the NF-κB pathway adds a
further level of complexity to the cross-talk between
these molecules. Our data demonstrate that PKM2 is
able to regulate the NF-κB as well as the HIF-1α signal-
ing pathways and suggest that the kinase acts upstream
of these two transcription factors in pancreatic tumors.
Interestingly, ectopic expression of p65 restored HIF-1α
transcriptional activity in hypoxic cells featuring PKM2
knock-down. In the same cells however, overexpression
of HIF-1α showed only marginal effect on NF-κB tran-
scription. While ectopic expression of p65/RelA resulted
in augmented HIF-1α transcription already in normoxic
condition, the overexpression of PKM2 had no impact
on HIF-1 promoter activity in cells with abrogated p65.
These data place the NF-κB p65 subunit below PKM2
and upstream of HIF-1α in the hypoxia signaling axis.
Conclusion
In conclusion, our data favor a scenario where the hyp-
oxic insult/intratumoral hypoxia is followed by trans-
location of PKM2 and p65 to the nucleus in pancreatic
cancer cells. Following the interaction, NF-κB subunit
p65 activates the transcription of HIF-1α and its target
genes, such as VEGF-A. As a result, augmented secre-
tion of VEGF translates to a boost in blood vessel forma-
tion that in turn contributes to tumor growth (Fig. 7).
Since VEGF is a target of both HIF-1α and NF-κB, we
cannot exclude the contribution of VEGF secretion as a
result of sole NF-κB activation or HIF-1α accumulation
in other tumor entities. We also think that basal HIF-1α
protein levels are critical for the cell’s readiness to re-
spond to hypoxia, and therefore render NF-κB to be crit-
ical for the degree and speed towards HIF-1α activation
after a hypoxic onslaught.
Since in human pancreatic ductal adenocarcinoma
(PDAC) HIF-1α expression highly correlates with tumor
size and poor prognosis [31] it will be a demanding task
to dissect the different signaling states and the potential
of feed-back signaling loops which may be of great im-
portance for therapeutic targeting of pancreatic tumors
using PKM2 inhibitors currently under intense
development.
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Additional file 1: Figure S1. 34 human pancreatic specimens were
stained with PKM2 and CD31 antibodies. Representative images are
shown. (PPTX 760 kb)
Additional file 2: Figure S2. IHC of pancreatic cancer cells growing on
CAM using specific antibodies directed against desmin and von
Willebrand factor (vWF) is presented. The images reveal both intratumoral
and extratumoral immunoreactivity of the endothelial markers.
(PPTX 4480 kb)
Additional file 3: Figure S3. PKM2 abrogation results in decreased
blood vessel formation in vivo. IHC of BxPC3 pancreatic cancer cells
growing on CAM using specific antibodies for desmin and von
Willebrand factor (vWF) is presented. (PPTX 3897 kb)
Additional file 4: Figure S4. PKM2 regulates hypoxia-induced HIF-1α
accumulation. A, B, pancreatic cancer cells transduced with a non-
targeting control shRNA or PKM2-specific shRNAs were incubated under
hypoxia or normoxia for 8 h. HIF-1α levels were determined using
western blot analysis. Quantification of HIF-1α band intensity was
conducted using ImageJ software (No – normoxia; Hy – hypoxia).
(PPTX 72 kb)
Additional file 5: Figure S5. PKM2 regulates hypoxia-induced VEGF
promoter activity. A, PaTu2 cancer cells were transiently transfected with
3xHRE-luc and pTK-Renilla. Four hours after transfection cells were incubated
under normoxic or hypoxic conditions in the absence or presence of 30 μM
TEPP-46. Cell lysates were subjected to luciferase assay. Bars are the means
+/- SEM of at least two independent experiments performed in duplicate. B,
cancer cells were transiently transfected with VEGF-luc and pTK-Renilla. Four
hours after transfection cells were incubated under normoxic or hypoxic
conditions in the absence or presence of 30 μM TEPP-46. Cell lysates were
subjected to luciferase assay. Bars are the means +/- SEM of at least two
independent experiments performed in duplicate. C, D, PaTu2 and Capan1
cells were transiently transfected with VEGF-luc reporter. Four hours later
cells were incubated under normoxic or hypoxic conditions in the absence
or presence of 10 μM BAY 87-2243. Lysates were subjected to luciferase
assay. Bars are the means +/- SEM of at least two independent experiments
performed in duplicate (No – normoxia; Hy – hypoxia). (PPTX 138 kb)
Additional file 6: Figure S6. PKM2 mediates hypoxia-triggered VEGF-A
secretion by activation of NF-κB/p65 subunit. A, western blot showing
the expression of YFP-p65 in PaTu2 pancreatic cancer cells is presented.
B, PaTu2 cancer cells with abrogated PKM2 were transiently co-
transfected with p65 expression plasmid and VEGF-A-luc reporter before
incubation in low oxygen atmosphere. Luciferase was measured after 24 h.
C, supernatants of PaTu2 cells with deleted PKM2 and overexpressing p65
cultivated in O2-deprived atmosphere or normoxia were subjected to VEGF-
A-specific ELISA. Bars are the means +/- SEM of at least two independent
experiments conducted in duplicate (No – normoxia; Hy – hypoxia).
(PPTX 119 kb)
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